The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | V | Various | |
| 2 | V10 | Therapeutic radiopharmaceuticals | |
| 3 | V10X | Other therapeutic radiopharmaceuticals | |
| 4 | V10XX | Various therapeutic radiopharmaceuticals | |
| 5 | V10XX03 |
| Active Ingredient | Description | |
|---|---|---|
| Radium-223 dichloride |
Radium-223 dichloride mimics calcium and selectively targets bone, specifically areas of bone metastases, by forming complexes with the bone mineral hydroxyapatite. Radium-223 dichloride monotherapy or in combination with luteinising hormone releasing hormone (LHRH) analogue is indicated for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC). |
| Title | Information Source | Document Type | |
|---|---|---|---|
| XOFIGO Solution for injection | European Medicines Agency (EU) | MPI, EU: SmPC |
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.
